Literature DB >> 24436242

Regulation of HIF-1 alpha by the proprotein convertases furin and PC7 in human squamous carcinoma cells.

Jian Fu1,2, Jirong Zhang1,2, Yulan Gong1, Courtney Lyons Testa1,2, Andres J Klein-Szanto1,2.   

Abstract

Proprotein convertases (PC), a family of serine proteases, process cancer-related substrates such as growth factors, growth factor receptors, cell adhesion molecules, metalloproteinases, etc. HIF-1α is a major transcription factor involved in tumorigenesis by sensing intratumoral hypoxia. Furin (PCSK3) is one of the numerous target genes regulated by HIF-1α transactivation and its distribution into endosomal compartments and onto the cell surface can be triggered by hypoxia via HIF-1α. siRNAs to knockdown PCs were transfected into cells alone or in combination with different drug treatments. Protein and RNA expression levels were analyzed by Western blotting or RT-PCR, respectively. PC7 (PCSK7) and furin siRNAs upregulated HIF-1α protein under normoxic condition to a level similar to that obtained by cobalt chloride treatment, eventually leading to activation of VEGF-A synthesis in two human head and neck squamous cell carcinoma cell lines. The unchanged levels of HIF-1α mRNA expression under siRNA treatment and the additive HIF-1α induction of PC siRNAs and either cobalt chloride or the 26S ribosome inhibitor, MG-132, suggested a post-transcriptional PC-mediated regulation. Furthermore, cycloheximide chase showed that PC7/furin siRNA regulation occurred at the level of HIF-1α translation. A specific IGF-1R signaling inhibitor was able to attenuate the PC siRNA induction of HIF-1α, suggesting the involvement of the IGF-1R pathway. Thus, the data show that PCs regulate HIF-1α. Furin and PC7 siRNAs induced HIF-1α protein by increasing its translation, resulting in upregulation of VEGF-A. This finding may provide insight into intricate PC functions that seem to be independent from their substrate-processing activity.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  HIF-1α regulation; PC7; cancer cells; furin; proprotein convertases

Mesh:

Substances:

Year:  2014        PMID: 24436242      PMCID: PMC4101078          DOI: 10.1002/mc.22131

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  48 in total

1.  Molecular Validation of PACE4 as a Target in Prostate Cancer.

Authors:  François D'Anjou; Sophie Routhier; Jean-Pierre Perreault; Alain Latil; David Bonnel; Isabelle Fournier; Michel Salzet; Robert Day
Journal:  Transl Oncol       Date:  2011-06-01       Impact factor: 4.243

Review 2.  Hypoxia-inducible factors in physiology and medicine.

Authors:  Gregg L Semenza
Journal:  Cell       Date:  2012-02-03       Impact factor: 41.582

3.  PACE4 expression in mouse basal keratinocytes results in basement membrane disruption and acceleration of tumor progression.

Authors:  Daniel E Bassi; Ricardo Lopez De Cicco; Jonathan Cenna; Samuel Litwin; Edna Cukierman; Andres J P Klein-Szanto
Journal:  Cancer Res       Date:  2005-08-15       Impact factor: 12.701

Review 4.  The proprotein convertases, 20 years later.

Authors:  Nabil G Seidah
Journal:  Methods Mol Biol       Date:  2011

5.  Elevated furin expression in aggressive human head and neck tumors and tumor cell lines.

Authors:  D E Bassi; H Mahloogi; L Al-Saleem; R Lopez De Cicco; J A Ridge; A J Klein-Szanto
Journal:  Mol Carcinog       Date:  2001-08       Impact factor: 4.784

6.  Hypoxia enhances cancer cell invasion through relocalization of the proprotein convertase furin from the trans-Golgi network to the cell surface.

Authors:  Dominique Arsenault; Fabrice Lucien; Claire M Dubois
Journal:  J Cell Physiol       Date:  2012-02       Impact factor: 6.384

7.  Regulation of hypoxia-inducible factor (HIF)-1 activity and expression of HIF hydroxylases in response to insulin-like growth factor I.

Authors:  Caroline Treins; Sophie Giorgetti-Peraldi; Joseph Murdaca; Marie-Noëlle Monthouël-Kartmann; Emmanuel Van Obberghen
Journal:  Mol Endocrinol       Date:  2005-02-03

8.  Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth.

Authors:  Ada Girnita; Leonard Girnita; Fabrizio del Prete; Armando Bartolazzi; Olle Larsson; Magnus Axelson
Journal:  Cancer Res       Date:  2004-01-01       Impact factor: 12.701

9.  Alternative pathway for the role of furin in tumor cell invasion process. Enhanced MMP-2 levels through bioactive TGFbeta.

Authors:  Stephanie McMahon; Marie Hélène Laprise; Claire M Dubois
Journal:  Exp Cell Res       Date:  2003-12-10       Impact factor: 3.905

Review 10.  HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression.

Authors:  Brian Keith; Randall S Johnson; M Celeste Simon
Journal:  Nat Rev Cancer       Date:  2011-12-15       Impact factor: 60.716

View more
  4 in total

Review 1.  The proprotein convertase furin in cancer: more than an oncogene.

Authors:  Abdel-Majid Khatib; John W M Creemers; Zongsheng He
Journal:  Oncogene       Date:  2022-01-07       Impact factor: 8.756

2.  Shedding of cancer susceptibility candidate 4 by the convertases PC7/furin unravels a novel secretory protein implicated in cancer progression.

Authors:  Stéphanie Duval; Afnan Abu-Thuraia; Islam E Elkholi; Rui Chen; Deeptee Seebun; Janice Mayne; Jean-François Côté; Daniel Figeys; Nabil G Seidah
Journal:  Cell Death Dis       Date:  2020-08-20       Impact factor: 8.469

Review 3.  ROS-Mediated Therapeutic Strategy in Chemo-/Radiotherapy of Head and Neck Cancer.

Authors:  Gan Huang; Shu-Ting Pan
Journal:  Oxid Med Cell Longev       Date:  2020-07-22       Impact factor: 6.543

4.  Coronavirus in Hematologic Malignancies: Targeting Molecules Beyond the Angiotensin-Converting Enzyme 2 (ACE2) Wall in COVID-19.

Authors:  Evangelos Tsiambas; Vasileios Papanikolaou; Aristeidis Chrysovergis; Nicholas Mastronikolis; Vasileios Ragos; Nikolaos Kavantzas; Andreas C Lazaris; Efthymios Kyrodimos
Journal:  Pathol Oncol Res       Date:  2020-04-24       Impact factor: 3.201

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.